To address this challenge, several research groups have strategically focused on categorizing high-risk neuroblastomas into three distinct molecular groups, all consistently associated with poor outcomes, based on TMM status (the MNA, ALT, and TERT rearrangements groups) [[4], [5], [6],11,20]. This evidence concerns the gene GPT and neuroblastoma.